Abstract
The efficacy of tolevamer, a nonantimicrobial styrene derivative toxin-binding agent, in treating simulated Clostridium difficile infection in an in vitro human gut model was investigated. Tolevamer reduced neither the duration nor magnitude of cytotoxin activity by C. difficile, reflecting poor efficacy observed in recent phase III clinical trials.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Chlorocebus aethiops
-
Clostridioides difficile / drug effects
-
Clostridioides difficile / pathogenicity
-
Clostridium Infections / drug therapy
-
Clostridium Infections / microbiology
-
Cytotoxins / metabolism*
-
Enterocolitis, Pseudomembranous / drug therapy
-
Enterocolitis, Pseudomembranous / microbiology
-
Gastrointestinal Tract / microbiology*
-
Humans
-
Microbial Sensitivity Tests
-
Models, Biological
-
Neutralization Tests
-
Polymers / metabolism
-
Polymers / therapeutic use*
-
Sulfonic Acids
-
Treatment Outcome
-
Vero Cells
Substances
-
Cytotoxins
-
Polymers
-
Sulfonic Acids
-
styrenesulfonic acid polymer